Evidence Supports

Ventilation and Permissive Hypercapnia

- Permissive hypercapnia and gentle ventilation can decrease lung injury by preserving spontaneous respirations, avoiding high ventilator pressures, avoiding muscle relaxants and oversedation, and acceptance of lower preductal saturations >80% and allow patients to accommodate and stabilize (Boloker, et.al.)The primary treatment goal in atraumatic reversal of persistent pulmonary hypertension (PPHN) is avoiding over ventilation and barotrauma with gentle ventilation. A ventilation strategy aiming for preductal saturation between 80 and 95%, postductal saturation above 70% and arterial CO 2 levels between 50 and 70 mm Hg (6.9–9.3 kPa, permissive hypercapnia) is well accepted [17].
- The Mode of Ventilation does not appear to be related to outcome. Snoek et al., found no significant difference in combined outcome and development of Brochopulmonary dysplasia in the use of Conventional versus High Frequency Oscillatory Ventilation in management of CDH when taking into account the lung to head ratio (LHR), side and size of the defect, and position of the liver [18]. The infants were found to have a shorter duration of ventilation and inotrope support. Additionally, they were less likely to receive vasoactive medications, phosphodiesterase inhibitors or be placed on ECMO.

Other

- **Serial oxygenation index (OI)** has been shown to predict the survival of infants with CDH on day of life 1 (DOL 1) [14, 18]. The main determining factor in the survival of these infants is the severity of pulmonary hypoplasia and persistent pulmonary hypertension. Utilization of serial OI in management decisions for patients with CDH can assist with postnatal counseling regarding prognosis, guide escalation of therapy such as ECMO, and potentially guide timing of surgery. OI can be calculated according to the formula, OI =(MAPx FiO2x100)/PaO2. Consecutive blood gases with an OI of greater than 40 is generally considered an indication for ECMO [15].
- **B-type natriuretic peptide (BNP)** has been shown to be significantly increased in patients with pulmonary hypertension. Partridge et. al., describe serial BNP levels on DOL 1, post operative day 1, and weekly aids in guiding management decisions [11].
- **Surfactant therapy** is recommended in neonates < 34 weeks gestation with findings of atelectasis on chest x-ray suggestive of respiratory distress syndrome (RDS) [4]. Furthermore, surfactant is recommended in infants who underwent fetal tracheal occlusion (FETO) when the occlusion is released <48h prior to delivery. In addition, it does not appear to be effective therapy when PPHN is the primary diagnosis, but should be considered in the presence of associated parenchymal lung disease when there is a suspected surfactant deficiency or impairment as in RDS or meconium aspiration syndrome. Stark, et.al.
- **Echocardiogram** should be obtained within the first 24h of life to detect any associated cardiac defects and severity of pulmonary hypertension, described as bidirectional or right to left shunting at ductal and/or atrial level, bulging or flattening of the interventricular septum toward the left ventricle, and tricuspid regurgitation jet velocity on continuous wave doppler [6].
- **Dopamine** administration can ensure end organ perfusion and improve left ventricular function and right ventricular failure when hypotension is present. After hypovolemia is corrected and ensures adequate intravascular volume, Dopamine may be needed to manage initial systemic hypotension [22].
- **Sildenafil** is recommended as an adjunctive therapy for infants with PPHN refractory to iNO especially when OI exceeds 25, Abman et.al. Further, It may augment the pulmonary vasodilator effects of iNO. Intravenous Sildenafil should be considered in infants with severe pulmonary hypertension not responsive to iNO, and has been shown to improve oxygenation and cardiac output [17]. PH has been shown to resolve with prolonged Sildenafil therapy in patients with CDH with recommended dosing of 0.5mg-1mg/kg TID po.

Sildenafil administration should be delayed in extremely preterm infants until retinal vascularization is established. Kelly et. al, found that in a systematic review meta-analysis of three studies including 77 patients showed enteral sildenafil therapy had a reduction of mortality and improved oxygen levels, however, the studies were done in settings where iNO and HFOV were not available resources. Therefore, Stark et. al., does not recommend enteral Sildenafil as initial therapy if iNO is available and should only be considered in a resource limited setting since the data of its efficacy and safety are insufficient.

- **iNO**: In one retrospective review, evidence showed that iNO may improve PaO2, AA gradient, and PaO2/FiO2 ratio in patients with preserved ventricular function. In addition, iNO may lower the rate of patients requiring ECMO in the same group[8].
- **PGE**: In one small retrospective study where the average age of the participants was 11 days, researchers noted improved O2 in patients that received PGE. In that same study, researchers concluded that flow velocity in the ductus arteriosus was decreased with PGE. Using PGE prophylactically may decrease the duration of non-invasive ventilation, ventilatory support, and decrease the O2 requirement in these patients as compared to administering it reactively[9].

Evidence Against

- Surfactant therapy showed no benefit in the treatment of term infants > 37 weeks prenatally diagnosed with isolated CDH. The CDH study group identified 522 infants with similar demographic characteristics with the exception of race, and found that the use of ECMO and incidence of chronic lung disease were higher, and survival lower in the surfactant treatment arm than those not treated with surfactant [111].
- Nitric oxide(iNO) use may be associated with increased mortality. A prospective review of seventy centers in 13 countries with a total of 3367 infants in the Congenital diaphragmatic hernia study group registry revealed that iNO use is common but highly variable among the centers. 97.1% of all centers participating used iNO to treat patients with CDH both with and without the presence of pHTN. Furthermore, the use of iNO fails to reduce the risk of death and ECMO use [13].
- Kumar, et. al. suggest the poor response to iNO in CDH pulmonary hypertension may be secondary to preexisting pulmonary venous hypertension [6]. Ventricular dysfunction in CDH can lead to post capillary or pulmonary venous hypertension that does not respond to and may worsen with inhaled vasodilators .
- Systemic antibiotics are generally not indicated until timing of surgical repair, at which time perioperative antibiotics are administered. A postoperative course of one to 5 days is dependent on whether or not a patch was used [15].

Evidence Lacking/Inconclusive

- There does not exist sufficient evidence in the literature reviewed regarding the use of Steroids, Vasopressors, and prostaglandin.
- **Hydrocortisone** has been shown to decrease the need for inotropes in infants with refractory hypotension and may benefit infants with CDH and catecholamine-resistant hypotension following ECMO. However, there is no data to support that empiric treatment with hydrocortisone improves outcomes [22].
- **Prostacyclin**, inhaled or IV is a potential intervention in infants who fail to respond to iNO but is not recommended for routine use due to lack of data on the safety and efficacy of its use [22].
- Epinephrine can be used for PPHN, to increase systemic blood pressure and left ventricular output. However, increased left ventricular afterload due to increased pulmonary vascular resistance in these infants may exacerbate right ventricular afterload [22].
- **Nitric oxide** has been shown in several studies to have no long term benefits in patients with CDH, however, iNO administration has been shown to improve oxygenation and decrease the need for ECMO in patients with normal left ventricular function [4].

Practice Recommendations

Delivery Room Management

Preparation

1. Notification of on-call pediatric surgeon of delivery plan
2. Team huddle with discussion of plan of care and clearly defined team member roles.
3. Advanced preparation of supplies including intubation equipment, 10 French replogle, ECG leads, pulse oximeter, potential normal saline fluid boluses, and resuscitative medications and supplies. Infant Code Blue cart should be immediately available.
4. T-piece resuscitator should be set with PEEP of 5 and PIP of 20 initially. May be increased to 25 cm H20 as needed
5. Drager ventilator

Initial Management

1. Immediate intubation without performing bag mask ventilation
2. Place pre-ductal pulse oximeter and ECG leads
3. Place the infant on volume-controlled ventilation as soon as feasible. Pressure controlled ventilation may be needed for transport from the resuscitation room to the NICU.
   a. PEEP 4-5 cm H20
   b. TV : 4-5 ml/kg
   c. MAX PIP 25
   d. Rate : 40 breaths per minute
   e. IT : 0.35 seconds
4. Initiate FiO2 at 40% and titrate as needed.
   a. Target pre-ductal saturations > 70% for the first ten minutes of life and then 80-95% in delivery room
5. Adjust ventilator settings (TV and PEEP) as indicated for respiratory distress or pre-ductal saturations less than target goal.
6. May use T-piece resuscitator as needed if unable to maintain appropriate saturations and arrange for HFOV use upon NICU admission
7. No routine surfactant administration. May consider if infant is premature < 37 weeks or has undergone Fetal Endoluminal Tracheal Occlusion (FETO)
8. Insert 10 French replogle and place to low continuous suction
9. Place peripheral IV.
   a. If unable to obtain IV access peripherally after two attempts, transfer to NICU.
10. Start D10W at 60 ml/kg/day for term infants. May be adjusted based on gestational age.
11. If poor perfusion or mean arterial pressure < gestational age, consider 10 ml/kg normal saline bolus
12. Transfer to NICU.

NICU Management

Monitoring and Vascular Access

1. Pre- and post-ductal pulse oximetry
2. Routine NICU intensive care monitoring
3. Place umbilical arterial catheter and umbilical venous catheter
   a. If appropriately placed UVC cannot be obtained, low-lying UVC may be left in place until alternative access is obtained
   b. If unable to obtain appropriately placed UAC, place a peripheral arterial line.

4. Consider PICC line placement prior to surgery, especially for right-sided defects.
5. Chest X-ray should be performed as soon as possible to confirm the diagnosis, assess severity and confirm position of ETT and replogle.

Ventilation

1. Tidal volume and PEEP should be adjusted to meet optimal physiological parameters of
   a. Pre-ductal saturations > 85% after two hours of life. May tolerate > 70% in the first two hours of life if other parameters are met and saturations are improving. Post-ductal saturation goal above 70%.
   b. pH > 7.25
   c. pCO2 between 50-70
   d. pO2 between 40-90
2. After stabilization, reduce FiO2 if the pre-ductal saturation is above 95%. Wean slowly by ~3% per hour to maintain pre-ductal saturations > 85%.
3. If unable to maintain above physiologic parameters with PIP Max of 25, infant should be transitioned to High Frequency Oscillatory Ventilation
   a. Initial MAP 13-17 cmH20
   b. Initial Hz 10
   c. Initial amplitude 30-50 cmH20
   d. Regular chest x-rays should be performed to avoid over-inflation
4. Oxygenation index and PEP scores should be monitored Q1-4 hours with ABGs to determine potential eligibility for ECMO
5. Consider changing to High Frequency Oscillatory Ventilation (HFOV) if unable to maintain pCO2 in goal range with PIP ≤ 28 adjust HFOV MAP and Delta P to meet physiology monitoring parameters to max MAP 19
6. Consider ECMO if unable to meet goal saturations or pCO2 on max HFOV settings.

Hemodynamic Management

1. Goal is to achieve appropriate end-organ perfusion determined by heart rate, urine output, and lactate levels.
2. If heart rate is normal, urine output is > 1 ml/kg/hr and lactate is < 3, and there are no other symptoms of poor tissue perfusion, vasopressor support is not required.
3. Echocardiography should be performed if there is poor perfusion, low blood pressure, or low saturations, which may distinguish between hypovolemia and myocardial dysfunction
4. Normal saline boluses of 10-20 ml/kg may be given as needed for poor perfusion, low blood pressure, and hypovolemia.
5. After two normal saline boluses, inotropic support should be added.
6. If concern for hypovolemic or vasodilatory shock, initiate the following:
   a. Initiate dopamine at 5 mcg/kg/min and titrate to a maximum dose of 20 mcg/kg/min.
   b. If vasopressor resistant hypotension, consider addition of hydrocortisone 1 mg/kg Q8-12H.
   c. If dopamine reaches 20 mcg/kg/min, consider adding epinephrine.
   d. Start epinephrine at 0.05 mcg/kg/min and titrate to a maximum dose of 1 mcg/kg/min.
7. If echo demonstrates the following, consider the following modifications to first-line vasopressor selection:
   a. Myocardial dysfunction: Initiate dobutamine at 5 mcg/kg/min and titrate to maximum dose of 20 mcg/kg/min.
   b. Significant pulmonary hypertension with systemic hypotension:
      i. Milrinone 0.5 mcg/kg/min and may be titrated to 0.7 mcg/kg/min
      ii. Initiate norepinephrine at 0.05 mcg/kg/min and titrate as needed to a maximum of 1 mcg/kg/min OR vasopressin at 0.0002 units/kg/min and titrate as needed to 0.01 units/kg/min.

Pulmonary Hypertension

1. Echocardiography should be performed within the first 24 hours on all infants. Sooner if the infant is showing signs of poor perfusion, hypotension, hypoxemia, or acidosis.
2. If preductal saturations fall below 85% and/or there are signs of poor organ perfusion, treatment of pulmonary hypertension should be initiated.
3. Milrinone should be initiated dose 0.5 mcg/kg/min and may be titrated to 0.7 mcg/kg/min for all infants with concern for pulmonary hypertension
4. iNO can be initiated in a time limited trial if there is evidence of an extra-pulmonary right to left shunt, and the OI is > 20 and/or a pre- and postductal saturation difference of 10% or more.
    a. Potential contraindications to iNO initiation: Left ventricular dysfunction, left atrial enlargement, and small left sided structures
    b. Trial of iNO may be for at least one hour
    c. If no effect after initiation, and administered for less than 4 hours, iNO should be discontinued without weaning. If administered for >4 hours, initiate Ascension Seton Neonatal iNO protocol. One study demonstrated that more infants treated with iNO required ECMO.
    d. iNO responders are defined by
        i. Decline of 10-20% in pre- postductal saturation difference
        ii. PaO2 increase of 10-20%
        iii. Improvement in hemodynamics including a decrease in lactate levels or a 10% increase in mean blood pressure.
5. Intravenous sildenafil 0.5 mg/kg IV q6hr should be considered in infants with severe pulmonary hypertension (administer over AT LEAST an hour to avoid hypotension)
6. In the setting of suprasystemic pulmonary hypertension and right to left shunting through the PDA/PFO, alprostadil should be considered to keep open the PDA and decrease afterload helping to protect the right ventricle.

Sedation and Paralysis

1. Initiate Dexmedetomidine (Precedex) as first line agent. Start at 0.3 mcg/kg/hr and titrate Q20 minutes by 0.1 mcg/kg/hr to max of 2 mcg/kg/hr.
2. Initiate Fentanyl infusion at 1 mcg/kg/hr and titrate to desired sedation level as needed for additional sedation or pain control
3. Midazolam (Versed) 0.1 mg/kg q2-4hr
4. Avoid paralysis if possible, but may be required.

Fluids/Electrolytes/Nutrition

1. D10 at 60 ml/kg/day should be initiated for term infants. Volume may be adjusted based on gestational age and birthweight.
2. Infants < 1500 grams, should be initiated on starter TPN
3. Infants are maintained NPO with replogle to low continuous suction.
4. Parenteral nutrition should be advanced per NICU feeding guidelines.
5. Post-operatively and after return of bowel function and hemodynamic stability, enteral nutrition should be initiated and advanced as tolerated per NICU feeding guidelines.

Laboratory/Radiographic Analysis

1. Admission: ABG, lactate, CBC with differential, Type and Screen, and blood culture if concern for sepsis
2. ABG, lactate q1-4 hr after NICU admission depending on clinical status
3. Methemoglobin daily if applicable for monitoring of iNO
4. 24 hours of life: BNP, BMP, total bilirubin, and chromosomal microarray
5. Chest x-ray with KUB on admission and daily prior to repair.

6. Newborn screening per protocol
7. BNP should be obtained weekly, before surgery, post-operative day 1, and as needed.

Antimicrobial Therapy

1. Not routinely indicated
2. Thirty-six hours of empiric antibiotics as dictated by maternal risk factors for infection and concern for sepsis

Transport to Dell Children's

1. A plan should be made for transfer to Dell Children's Medical Center NICU once stabilized and umbilical lines are placed.
2. If infant meets ECMO criteria and does not have congenital heart disease, infant should be transported to the DCMC Pediatric ICU
   a. Neonatology should be consulted after arrival
3. If infant meets ECMO criteria and does have congenital heart disease, infant should be transported to the Cardiac Care Unit
   a. Neonatology should be consulted after arrival

Consultations and Discharge Planning

1. Pediatric surgery should be notified prior to delivery, updated after delivery, notified of the plan for transport, and notified upon arrival to DCMC.
2. Pediatric Pulmonology should be consulted prior to discharge on all patients with CDH with plan for follow-up for at least the first three years of life
3. Pediatric cardiology should be consulted on all patients with abnormal echos and follow as an outpatient if the patient remains on oxygen at the time of discharge or as needed.
4. Pediatric gastroenterology as needed for symptoms of GER, dysmotility, etc.
5. Neurodevelopmental follow-up should be in place for all patients at the time of discharge.
   a. MRI should be performed prior to discharge in all patients with abnormal head ultrasound findings, abnormal neurologic exam, history of seizures, need for ECMO or who required a patch repair
6. See recommended schedule of follow-ups.

References

1. Boloker, Judd, David A Bateman, Jen-Tien Wung, and Charles J h Stolar. "Congenital Diaphragmatic Hernia in 120 Infants Treated Consecutively with Permissive Hypercapnea/Spontaneous Respiration/Elective Repair." Journal of Pediatric Surgery 37, no. 3 (March 2002): 357–66. https://doi.org/10.1053/jpsu.2002.30834.
2. Davey, Marcus G, Holly L Hedrick, Sarah Bouchard, Julianne M Mendoza, Uwe Schwarz, N Scott Adzick, and Alan W Flake. "Temporary Tracheal Occlusion in Fetal Sheep with Lung Hypoplasia Does Not Improve Postnatal Lung Function." Journal of Applied Physiology 94, no. 3 (March 1, 2003): 1054–62. https://doi.org/10.1152/japplphysiol.00733.2002.
3. Finer, N N, A Tierney, P C Etches, A Peliowski, and W Ainsworth. "Congenital Diaphragmatic Hernia: Developing a Protocolized Approach." Journal of Pediatric Surgery 33, no. 9 (September 1998): 1331–37. https://doi.org/10.1016/s0022-3468(98)90001-x.
4. Hedrick, Holly L. "Management of Prenatally Diagnosed Congenital Diaphragmatic Hernia." Seminars in Pediatric Surgery 22, no. 1 (February 2013): 37–43. https://doi.org/10.1053/j.sempedsurg.2012.10.007.
5. Klaassens, M, A de Klein, and D Tibboel. "The Etiology of Congenital Diaphragmatic Hernia: Still Largely Unknown?" European Journal of Medical Genetics 52, no. 5 (2009): 281–86. https://doi.org/10.1016/j.ejmg.2009.05.005.
6. Kumar, Vasantha H S, Rita Dadiz, Jamie Koumoundouros, Stephanie Guilford, and Satyan Lakshminrusimha. "Response to Pulmonary Vasodilators in Infants with Congenital Diaphragmatic Hernia." Pediatric Surgery International 34, no. 7 (July 2018): 735–42. https://doi.org/10.1007/s00383-018-4286-5.
7. Lally, Kevin P, and William Engle. "Postdischarge Follow-up of Infants with Congenital Diaphragmatic Hernia." Pediatrics 121, no. 3 (March 2008): 627–32. https://doi.org/10.1542/peds.2007-3282.
8. Lawrence, Kendall M, Stylianos Monos, Samantha Adams, Lisa Herkert, William H Peranteau, David A Munson, Rachel K Hopper, Catherine M Avitabile, Natalie E Rintoul, and Holly L Hedrick. "Inhaled Nitric Oxide Is Associated with Improved Oxygenation in a Subpopulation of Infants with Congenital Diaphragmatic Hernia and Pulmonary Hypertension." The Journal of Pediatrics 219 (April 2020): 167–72. https://doi.org/10.1016/j.jpeds.2019.09.052.
9. Duc, Kévin Le, Sébastien Mur, Dyuti Sharma, Estelle Aubry, Morgan Recher, Thameur Rakza, and Laurent Storme. "Prostaglandin E1 in Infants with Congenital Diaphragmatic Hernia (CDH) and Life-Threatening Pulmonary Hypertension." Journal of Pediatric Surgery 55, no. 9 (September 2020): 1872–78. https://doi.org/10.1016/j.jpedsurg.2020.01.008.
10. O'Toole, S J, H L Karamanoukian, M S Irish, A Sharma, B A Holm, and P L Glick. "Tracheal Ligation: The Dark Side of in Utero Congenital Diaphragmatic Hernia Treatment." Journal of Pediatric Surgery 32, no. 3 (March 1997): 407–10. https://doi.org/10.1016/s0022-3468(97)90592-3.
11. Partridge, Emily A, Brian D Hanna, Natalie E Rintoul, Lisa Herkert, Alan W Flake, N Scott Adzick, Holly L Hedrick, and William H Peranteau. "Brain-Type Natriuretic Peptide Levels Correlate with Pulmonary Hypertension and Requirement for Extracorporeal Membrane Oxygenation in Congenital Diaphragmatic Hernia." Journal of Pediatric Surgery 50, no. 2 (February 2015): 263–66. https://doi.org/10.1016/j.jpedsurg.2014.11.009.
12. Puligandla, Pramod S, Julia Grabowski, Mary Austin, Holly Hedrick, Elizabeth Renaud, Meghan Arnold, Regan F Williams, et al. "Management of Congenital Diaphragmatic Hernia: A Systematic Review from the APSA Outcomes and Evidence Based Practice Committee." Journal of Pediatric Surgery 50, no. 11 (November 2015): 1958–70. https://doi.org/10.1016/j.jpedsurg.2015.09.010.
13. Putnam, Luke R, Kuojen Tsao, Francesco Morini, Pamela A Lally, Charles C Miller, Kevin P Lally, and Matthew T Harting. "Evaluation of Variability in Inhaled Nitric Oxide Use and Pulmonary Hypertension in Patients

With Congenital Diaphragmatic Hernia." JAMA Pediatrics 170, no. 12 (December 2016): 1188–94. https://doi.org/10.1001/jamapediatrics.2016.2023.

14. Ruttenstock, Elke, Naomi Wright, S Barrena, Annika Krickhahn, Christoph Castellani, Ashish P Desai, Risto Rintala, et al. "Best Oxygenation Index on Day 1: A Reliable Marker for Outcome and Survival in Infants with Congenital Diaphragmatic Hernia." European Journal of Pediatric Surgery : Official Journal of Austrian Association of Pediatric Surgery ... [et Al] = Zeitschrift Fur Kinderchirurgie 25, no. 1 (February 2015): 3–8. https://doi.org/10.1055/s-0034-1393960.
15. Skarsgard, E. D., and M. R. Harrison. "Congenital Diaphragmatic Hernia: The Surgeon's Perspective." Pediatrics in Review / American Academy of Pediatrics 20, no. 10 (1999). https://doi.org/10.1542/pir.20-10-e71.
16. Snoek, Kitty G, Irma Capolupo, Joost van Rosmalen, Lieke de Jongste-van den Hout, Sanne Vijfhuize, Anne Greenough, René M Wijnen, Dick Tibboel, and Irwin K M Reiss. "Conventional Mechanical Ventilation Versus High-Frequency Oscillatory Ventilation for Congenital Diaphragmatic Hernia: A Randomized Clinical Trial (The VICI-Trial)." Annals of Surgery 263, no. 5 (May 2016): 867–74. https://doi.org/10.1097/SLA.0000000000001533.
17. Snoek, Kitty G, K M Reiss, and Anne Greenough. "Standardized Postnatal Management of Infants with Congenital Diaphragmatic Hernia in Europe : The CDH EURO Consortium Consensus – 2015 Update," 2016, 66–74. https://doi.org/10.1159/000444210.
18. Tan, Yew-Wei, Louise Adamson, Christopher Forster, Brian Davies, and Don Sharkey. "Using Serial Oxygenation Index as an Objective Predictor of Survival for Antenatally Diagnosed Congenital Diaphragmatic Hernia." Journal of Pediatric Surgery 47, no. 11 (November 1, 2012): 1984–89. https://doi.org/10.1016/j.jpedsurg.2012.07.039.
19. Meurs, Krisa Van, and the Congenital Diaphragmatic Hernia Study Group. "Is Surfactant Therapy Beneficial in the Treatment of the Term Newborn Infant with Congenital Diaphragmatic Hernia?" The Journal of Pediatrics 145, no. 3 (September 1, 2004): 312–16. https://doi.org/10.1016/j.jpeds.2004.04.056.
20. Weems, Mark F, Tim Jancelewicz, and Hitesh S Sandhu. "Congenital Diaphragmatic Hernia: Maximizing Survival." NeoReviews 17, no. 12 (December 1, 2016): e705 LP-e718. https://doi.org/10.1542/neo.17-12-e705.

Appendix 1 – Neonatal Inhaled Nitric Oxide Protocol



- **PHYSICIAN MUST BE CALLED BEFOFE INITIATION AND REINITIATION AFTER FAILED ATTEMPT**
- Call physician to initiate weaning protocol when patient stable with following:
- PaO2 > 80%
- FiO2 of less than or equal to 60%
- If patient fails weaning, return to lowest effective dose of iNO, call the physician and attempt weaning in 24 hours
- If methemoglobin of greater than 5 % is detected, call physician to wean iNO
- Consider increasing FiO2 10 – 20% prior to discontinuing iNO
- Patient should have an ordered SpO2 parameter ordered before placement on the weaning protocol

OI = (Paw xFiO2)/PaO2
Paw = Mean Airway Pressure
Pa02 = Partial Arterial Oxygen Pressure
MAP = Mean Arterial Pressure
PAP = Pulmonary Artery Pressure
*Used only if measured available

Appendix 2 – Recommended Schedule of Follow-up for Patients with CDH

TABLE 1 Recommended Schedule of Follow-up for Infants With CDH

	Before Discharge	1–3 mo After Birth	4–6 mo After Birth	9–12 mo After Birth	15–18 mo After Birth	Annual Through 16 y
Weight, length, occipital-frontal circumference	X	X	X	X	X	X
Chest radiograph	X	If patched	If patched	If patched	If patched	If patched
Pulmonary function testing			If indicated		If indicated	If indicated
Childhood immunizations	As indicated throughout childhood	X	X	X	X	X
RSV prophylaxis	RSV season during first 2 years after birth (if evidence of chronic lung disease)	X	X	X	X	X
Echocardiogram and cardiology follow-up	X	If previously abnormal or if on supplemental oxygen	If previously abnormal or if on supplemental oxygen	If previously abnormal or if on supplemental oxygen	If previously abnormal or if on supplemental oxygen	If previously abnormal or if on supplemental oxygen
Head computed tomography or MRI	If (1) abnormal finding on head ultrasound; (2) seizures/abnormal neurologic findings[a]; or (3) ECMO or patch repair	As indicated	As indicated	As indicated	As indicated	As indicated
Hearing evaluation[44]	Auditory brainstem evoked response or otoacoustic emissions screen	X	X	X	X	Every 6 mo to age 3 y, then annually to age 5 y
Developmental screening evaluation	X	X	X	X		Annually to age 5 y
Neurodevelopmental evaluation	X			X		Annually to age 5 y
Assessment for oral feeding problems	X	X	If oral feeding problems	If oral feeding problems	If oral feeding problems	If oral feeding problems
Upper gastrointestinal study, pH probe, and/or gastric scintiscan	Consider for all patients	If symptoms	If symptoms	Consider for all patients	If symptoms	If symptoms
Esophagoscopy		If symptoms	If symptoms	If symptoms or if abnormal gastrointestinal evaluations	If symptoms	If symptoms
Scoliosis and chest wall deformity screening (physical examination, chest radiograph, and/or computed tomography of the chest)				X		X

The neurosensory tests performed and frequency of surveillance may differ among infants with CDH because of variability in neurologic, developmental, and physiologic impairments. Follow-up should be tailored to each infant. RSV indicates respiratory syncytial virus.
[a] Muscle weakness, hypotonia, hypertonia, or other abnormal neurologic sign or symptom.